Drug Profile
Research programme: acute myelogenous leukaemia therapy - Provid Pharmaceuticals/The Leukemia & Lymphoma Society
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Provid Pharmaceuticals; The Leukemia & Lymphoma Society
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA
- 10 Jun 2008 Early research in Acute myeloid leukaemia in USA (unspecified route)